Randomized, dose-escalation study of the p38a MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis with peripheral cytopenias and increased propensity for progression to acute myeloid leukemia. 1 p38 mitogen-activated protein kinase (MAPK) belongs to a family of widely expressed serine-threonine kinases, 2 which include four isoenzymes (a,b,g and d) encoded by different genes with distinct tissue expression patterns. In bone marrow biopsy sections from patients with lower-risk MDS, immunohistochemical staining revealed constitutive activation of p38a MAPK in bone marrow precursors irrespective of morphologic subtype. 3, 4 Increased phosphorylation of p38a MAPK correlated with interleukin (IL)-1b expression level and cleaved caspase-3, implicating the signaling pathway in the apoptotic response in MDS. 5 We investigated the safety and tolerability, as well as hematologic response and pharmacodynamics, of SCIO-469 (indole-5-carboxamide), a potent selective adenosine triphosphate-competitive inhibitor of p38a MAPK. 5, 6 We conducted the phase I/II randomized, open-label, multicenter, modified parallel dose escalation study in patients with low-and intermediate-1-risk MDS classified according to International Prognostic Scoring System (IPSS) 7 who did not respond to prior treatment with a recombinant erythropoietin. The protocol was approved by the Institutional Review Board at each participating institution, and all patients provided informed written consent.
Between April 2005 and May 2006, we enrolled 62 patients at 10 centers in the United States (Table 1) . Eligible patients had a diagnosis of MDS of at least 8-week duration (see additional inclusion and exclusion criteria at ClinicalTrials.gov, identifier NCT00113893). Patients received pretrial screening within 35 days of study entry and clinical laboratory assessments every 2 weeks through week 16, every 4 weeks after week 16 and every 8 weeks after week 52. Bone marrow aspiration and biopsy were performed every 8 weeks through week 16, every 8 weeks through week 52 and every 6 months after week 52. Four dose levels of oral SCIO-469 were studied: 30 mg (90 mg per day; 15 patients), 60 mg (180 mg per day; 15 patients), 90 mg (270 mg per day; 15 patients) and 120 mg (360 mg per day; 17 patients) three times daily. Initially, patients were randomly assigned to receive either 90 mg per day or 180 mg per day. Randomization to the next higher-dose group was deferred until a successful first interim safety analysis was completed. The expansion to the 360 mg per day group was contingent on the results of a second interim safety analysis conducted after 15 subjects in each of the first three dose levels had been enrolled. Hematologic responses were assessed after 16 weeks of treatment according to modified International Working Group criteria. 8 Responders and those experiencing clinical benefit in the opinion of the investigator could continue the assigned treatment for up to 36 additional weeks. Similar criteria were applied at week 52 and week 78 to determine eligibility to continue treatment for an additional 26 weeks. Maximum treatment duration was 104 weeks.
Forty-seven patients completed treatment through week 16. Among the 15 patients who terminated the study prematurely, three withdrew because of a non-hematologic serious adverse event (AE), with two considered drug related (exacerbation of congestive heart failure at 180 mg per day and atrial fibrillation at 360 mg per day) and one non-drug related (grade 2 asthenia at 360 mg per day). Eight patients withdrew prematurely because of an AE (graded according to National Cancer Institute common toxicity criteria version 3.0 9 ), with two considered severe and drug related (grade 4 neutropenia at 270 mg per day and grade 3 elevation of alanine aminotransferase (ALT) at 360 mg per day). The remaining AEs included abdominal pain, malignant melanoma and colon cancer, all considered unrelated, as well as rash (360 mg per day), duodenal ulcer (360 mg per day) and elevated ALT (360 mg per day), which were considered possibly drug related. Four patients discontinued therapy prematurely for other reasons. Twelve patients qualified for and elected to continue treatment beyond week 16, with five completing treatment through week 52 but seven withdrawing before week 52 because of disease progression (two patients) or reasons unrelated to drug tolerance (five patients). There were no study-related deaths.
Most AEs were mild or moderate in severity, unrelated to study drug and easily managed. We documented 64 AEs of grade 3 severity or higher in 25 patients, with 19 events in 10 patients considered drug related. Two patients experienced drug-related grade 3 and 4 neutropenia (270 mg per day, 360 mg per day). Severe nonhematologic events thought to be drug-related were rash, abdominal pain and jaundice, gastric ulcer, chest tightness, angina, and atrial fibrillation. Twenty-seven of 56 evaluable patients experienced QT/QTc prolongation at one or more post-baseline assessments. None of the QT/QTc interval increases were associated with AEs.
Hematological improvement and bone marrow response had a minimum duration requirement of 8 weeks. Patients who achieved response at week 16 could continue on the same dose of SCIO-469 with periodic observation for disease progression, AEs or non-response. Eighteen of 62 patients (29%) experienced Accepted article preview online 11 September 2012; advance online publication, 2 October 2012
Letters to the Editor hematological improvement with responses in each hematopoietic lineage, and 11 (18%) achieved either a major (10%) or minor (8%) erythroid response, with all dose levels represented among responders (Table 2) . Median time to response was 72 days (range, 56-98 days), and duration of response ranged from 63 days to 42 years. One major platelet response (6%) was observed among 16 patients with thrombocytopenia at baseline in the 90 mg per day cohort; platelet response was accompanied by a major neutrophil response. Of 24 patients neutropenic at baseline, six (25%) achieved a major (three) or minor (three) neutrophil response, with responses in all dose levels. Bone marrow responses, disease progression and AML transformation were analyzed in 41 patients. One patient (2%) achieved a complete response with resolution of bone marrow cytologic dysplasia. A single partial response (2%) was achieved, occurring in a patient (270 mg per day) who had a minor erythroid response. Thirty-six patients (58%) had stable disease, and 5 (8%) experienced MDS progression. No subjects experienced AML transformation. One major cytogenetic response (7%) among a total of 15 evaluable patients with abnormal karyotype at baseline was achieved in a patient (360 mg per day) who also had a minor erythroid response.
After SCIO-469 administration, mean plasma concentration of SCIO-469 peaked at hour 1, with those for the metabolites generally peaking at hour 2. There was no evidence for accumulation of the study drug or its metabolites. Heat shock protein-27 (Hsp27), a downstream target of p38 kinase, whose phosphorylation is inhibited by SCIO-469, was tested in bone marrow aspirate lysates and peripheral blood mononuclear cells at baseline and at week 16. There was a trend favoring a decrease in the ratio of phospho-Hsp27 to total Hsp27 observed in all dosing cohorts, although no statistically significant dose-response relationship was apparent.
In summary, oral SCIO-469 administered at doses ranging from 90-360 mg daily was well tolerated in patients with lower-risk MDS and showed modest multilineage activity at all dose levels without reaching dose-limiting toxicity. However, bone marrow and cytogenetic responses were rare, suggesting that inhibition of p38a MAPK with SCIO-469 at dose levels tested in this trial is unlikely to have disease-altering activity. Interestingly, one transfusion-dependent patient achieved a complete remission with resolution of cytological dysplasias that has persisted for 42 years since study completion. Given that p38a MAPK is required for erythropoietin expression, pharmacological inhibition may attenuate endogenous erythropoietin response to anemia, raising consideration that SCIO-469 may yield greater erythropoietic activity in MDS when combined with an erythropoietic stimulating agent. 10 
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Some months after our article was published we got hold of 2 ml coagulated blood with 3% of abnormal cells from the same patient. As sequencing technology has also developed very fast lately, we decided to extract RNA from the sample and try to use it for high-throughput sequence analysis. The RNA was extracted and its quality checked by the Experion automated electrophoresis system (Bio-Rad Laboratories, Hercules, CA, USA). A total of 3 mg of RNA was sent for high-throughput pair-end RNAsequencing to the Norwegian Sequencing Center at the Ullevål Hospital (http://www.sequencing.uio.no/). The Illumina software pipeline was used to process image data into raw sequencing data and only sequence reads marked as 'passed filtering' were used in the downstream data analysis. A total of 107 million reads were obtained. The FASTQC software was used for quality control of the raw sequence data (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). We used the fusion discovery software FusionMap (release date 16-04-2012) 2 and the pre-built Human B37 and RefGene from the FusionMap website (http://www.omicsoft.com/ fusionmap/). A list of over 500 possible fusion genes was obtained. A specific fusion involving the CBFA2T3 gene, which maps to chromosome band 16q24, and the nuclear factor I/A (NFIA) gene, which maps to chromosome band 1p31, was identified as number 10 in the list (seed count-rank 48; Supplementary Table 1 ). The involvement of the NFIA gene fits well with the fluorescence in situ hybridization (FISH) data on chromosome 1 previously obtained and published. 1 The presence of the NFIA/CBFA2T3 fusion was verified by PCR using the NFIA-956 F and CBFA2T3-622 R primer combination (Supplementary Table 2 ). A specific PCR product of about 500 bp was identified and directly sequenced (Figure 1a) . The specific fusion occurs between exon 6 of the NFIA gene (accession number NM_001134673.3) and exon 3 of the CBFA2T3 gene (accession number NM_005187.5; Figure 1b) .
The NFIA/CBFA2T3 fusion gave an open reading frame and is expected to lead to a chimeric protein containing 208 amino-acid residues from NFIA (according to NP_001128145.1) and 603 residues from CBFA2T3 (according to NP_005178.4). The predicted fusion protein should thus consist of 811 amino acids (Figure 1c) .
The NFIA gene encodes a member of the NFI family of transcription factors (http://genome.ucsc.edu). Interestingly, it has been found that NFIA exhibits a marked lineage-specific expression pattern in normal human hematopoiesis; it is upregulated in the erythroid lineage but fully suppressed in granulocytopoiesis. 3 It has been shown that in early hematopoiesis, the NFIA expression level acts as a factor channeling hematopoietic progenitor cells into either the erythroid or granulocytopoietic lineage. 3 The NFI proteins have a DNA-binding and dimerization domain in their N-terminal half, which contains four cysteine residues, and a transactivation and repression domain in their C-terminal half. 4 The NFIA gene was found involved in an NFIA/EHF chimeric fusion in one breast cancer cell line out of 24 breast tumors analyzed (nine cell lines and 15 primary tumors). 5 However, its role as either a passenger event or a direct, albeit infrequent, contributor to breast cancer development remains uncertain.
CBFA2T3 encodes an ETO myeloid translocation gene family protein, which interacts with DNA-bound transcription factors and recruits a variety of corepressors to facilitate transcriptional repression. [6] [7] [8] The t(16;21)(q24;q22) translocation is one of the less common karyotypic abnormalities specifically associated with acute myeloid leukemia (AML). The translocation produces a chimeric gene made up of the 5'-region of the runt-related transcription factor 1 (RUNX1) gene fused to the 3 0 -region of CBFA2T3 (Figure 1d ). In AMLs with either t(8;21) or t(16;21), the transcription factor RUNX1 is juxtaposed to one of the zinc finger nuclear proteins CBFA2T1 and CBFA2T3, respectively, resulting in transcriptional repression of RUNX1 target genes. 6 Lately, its involvement as a partner in fusion genes was underlined by the identification of a IGH/CBFA2T3 fusion in a case of Burkitt lymphoma and a diffuse large B-cell lymphoma. 9 This gene is also a putative breast tumor suppressor. 10, 11 Interestingly, CBFA2T3 is downregulated during erythroid differentiation, and it has been Accepted article preview online 11 September 2012; advance online publication, 2 October 2012
